Article Text

THU0677 Outcome measurement instruments for safety in rheumatology: a scoping review of available instruments to inform the omeract safety working group
  1. L Klokker1,
  2. T Woodworth2,
  3. DE Furst2,
  4. P Tugwell3,
  5. D Devoe4,
  6. P Williamson5,
  7. CB Terwee6,
  8. ME Suarez-Almazor7,
  9. V Strand8,
  10. AL Leong9,
  11. N Goel10,
  12. M Boers11,
  13. PM Brooks12,
  14. LS Simon13,
  15. R Christensen1,
  16. on behalf of OMERACT working group
  1. 1The Parker Institute, Bispebjerg & Frederiksberg Hospital, Copenhagen, Denmark
  2. 2David Geffen School of Med., Division Rheumatology, UCLA, Los Angeles, United States
  3. 3Dept of Medicine, School of Epidemiology, Public Health and Community Medicine, University of Ottawa, Ottawa
  4. 4Department of Medicine, University of Calgary, Cumming School of Medicine, Calgary, Canada
  5. 5Institute of translational medicine, University of Liverpool, Liverpool, United Kingdom
  6. 6Department of Epidemiology and Biostatistics, the EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
  7. 7Section of Rheumatology and Clinical Immunology, University of Texas MD Anderson Cancer Center, Houston
  8. 8Div Imm/Rheum, Sanford University, San Fransisco
  9. 9Healthy Motivation, Global Alliance for Musculoskeletal Health, Bone and Joint Decade, Santa Barbara
  10. 10Advisory Services, Strategic Drug Development, Quintiles IMS, Morrisville NC, United States
  11. 11Department of Epidemiology and Biostatistics, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands
  12. 12Centre for Health Policy Melbourne School of Population, Global Health University of Melbourne, Melbourne, Australia
  13. 13SDG LLC Cambridge, Cambridge MA, United States


Background International scientific networks have raised concerns about inadequate reporting of safety outcomes in randomised trials and systematic reviews. Outcome Measures in Rheumatology (OMERACT) has previously developed an adaptation of the US National Cancer Institute (US NCI) Common Terminology Criteria for Adverse Events (CTCAE), the RCTC (Rheumatology Common Toxicity Criteria) to collect adverse events in rheumatology clinical trials. To respond to the need to also report safety outcomes from the patient perspective, the Safety Working Group is developing a core outcome set, followed by a core outcome measurement set. A scoping review of available instruments for measuring safety outcomes is needed to inform this work.

Objectives To identify candidate measurement instruments for safety outcomes in rheumatology clinical trials.

Methods A systematic search was performed in the MEDLINE database (via PubMed) in January 2017 using MeSH terms covering synonyms for adverse events, rheumatology and measurement instruments and the Boolean operator AND to combine them. Full-text articles about the development or evaluation of instruments for measuring safety in rheumatology were eligible. One reviewer (LK) screened for eligibility based on title and abstracts. Two reviewers (LK and RC) screened the full text articles.

Results Of 434 unique references identified, 19 were read in full-text, and 8 were included (see figure). The instruments identified were: Glucocorticoid Toxicity Index (GTI), Patient Reported Experiences and Outcomes of Safety in Primary Care (PREOS-PC), Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI flare index (cSFI), the BioSecure questionnaire, Rheumatology Common Toxicity Criteria (RCTC), OMERACT 3x3, and the Stanford Toxicity Index (STI). These instruments were specific for substance (GTI, BioSecure questionnaire), setting (PREOS-PC), condition (cSFI), or not fully validated (RCTC, OMERACT 3x3, STI).

Conclusions The instruments identified are either too specific, or require further development/evaluation, for the purpose of standardizing measurement of safety in rheumatology clinical trials. Thus, we will proceed to gain consensus on the domains that must be measured to develop a core outcome set.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.